High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention

EuroIntervention

Volumn 12, Issue 3, 2016, Pages 345-351

  Oemrawsingh, Rohit M ^a   Cheng, Jin M ^a   Martijn Akkerhuis, K ^a   Kardys, Isabella ^a   Degertekin, Muzaffer ^b   Van Geuns, Robert Jan ^a   Daemen, Joost ^a   Boersma, Eric ^a   Serruys, Patrick W ^a   Van Domburg, Ron T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b YEDITEPE UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Percutaneous coronary intervention; Prognosis

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROTEIN BLOOD LEVEL; SIROLIMUS ELUTING CORONARY STENT; SMOKING; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; AGED; BLOOD; DRUG ELUTING STENT; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; C-REACTIVE PROTEIN; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 84975816129     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY15M07_04     Document Type: Article

References (28)

1. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-19.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420: 868-74.
3. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
4. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54: 2129-38.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.
6. Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:2292-7.
7. Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, Aarden LA, van Rijswijk MH. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid a (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta. 1991;1091:405-8.
8. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A. Preprocedural serum levels of c-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512-21.
9. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, Schühlen H, Schömig A, Kastrati A. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003;114:715-22.
10. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE investigators. Chimeric c7E3 antiplatelet therapy in unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000;35:1535-42.
11. Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, van den Brand MJ, Hamm CW, Simoons ML; CAPTURE Investigators. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J. 2003;24:77-85.
12. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139-47.
13. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998;31:1460-5.
14. Lemos PA, Serruys PW, van Domburg RT, Saia F, Aram-patzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Gies-sen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-5.
15. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72; discussion 207-12.
18. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:1528-36.
19. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-908.
20. He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart. 2010;96:339-46.
21. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-40.
22. Park DW, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Kim YH, Lee CW, Kim JJ, Park SW, Park SJ. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation. 2009;120:1987-95.
23. Hartford M, Wiklund O, Mattsson Hulten L, Persson A, Karlsson T, Herlitz J, Caidahl K. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med. 2007;262:526-36.
24. Niccoli G, Montone RA, Ferrante G, Crea F The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56:1783-93.
25. Lasave LI, Abizaid AA, Paiva e Maia J, de Ribamar Costa J Jr, Feres F, Mattos LA, Abizaid AS, Siqueira DA, Tanajura LF, Staico R, Beraldo de Andrade P, Braga SN, Sousa AG, Sousa JE. [Relationship between plasma C-reactive protein level and neointi-mal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound]. Rev Esp Cardiol. 2007;60:923-31.
26. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Akkerhuis KM, Kardys I, de Boer SP, Langstraat JS, Regar E, Van Geuns RJ, Serruys PW, Boersma E. Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study). Am J Cardiol. 2014;114:1497-503.
27. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584-636.
28. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:III39-43.